Vanda Pharmaceuticals Inc. Share Price

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
6.24 USD -4.00% Intraday chart for Vanda Pharmaceuticals Inc. +1.96% +47.87%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 194M 15.34B Sales 2025 * 232M 18.33B Capitalization 363M 28.64B
Net income 2024 * -3M -237M Net income 2025 * -19M -1.5B EV / Sales 2024 * 0.9 x
Net cash position 2024 * 189M 14.9B Net Debt 2025 * 65.1M 5.13B EV / Sales 2025 * 1.84 x
P/E ratio 2024 *
-104 x
P/E ratio 2025 *
-18.9 x
Employees 203
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.00%
1 week+1.96%
Current month+22.11%
1 month+21.64%
3 months+64.21%
6 months+62.08%
Current year+47.87%
More quotes
1 week
5.81
Extreme 5.81
6.75
1 month
4.86
Extreme 4.86
6.75
Current year
3.46
Extreme 3.46
6.75
1 year
3.30
Extreme 3.295
6.76
3 years
3.30
Extreme 3.295
21.86
5 years
3.30
Extreme 3.295
21.86
10 years
3.30
Extreme 3.295
33.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 31/10/02
Director of Finance/CFO 40 30/11/12
Human Resources Officer - 31/07/19
Members of the board TitleAgeSince
Director/Board Member 82 30/11/05
Chief Executive Officer 64 31/10/02
Director/Board Member 72 13/02/20
More insiders
Date Price Change Volume
14/06/24 6.24 -4.00% 1,134,319
13/06/24 6.5 +9.80% 4,269,719
12/06/24 5.92 -1.17% 749,339
11/06/24 5.99 +0.17% 776,390
10/06/24 5.98 -2.29% 856,064

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.24 USD
Average target price
5.21 USD
Spread / Average Target
-16.51%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW